Loading grant details…
VACCELERATE - European Corona Vaccine Trial Accelerator Platform
| Funder | European Commission |
|---|---|
| Recipient Organization | Klinikum Der Universitaet Zu Koeln |
| Country | Based in EU |
| Start Date | Jan 28, 2021 |
| End Date | Jan 27, 2024 |
| Duration | 1,094 days |
| Number of Grantees | 35 |
| Roles | Participant; Third Party; Coordinator; Award Holder |
| Data Source | Europe PMC |
| Grant ID | 101037867 |
Grant Description
The ongoing COVID-19 pandemic creates an unprecedented burden worldwide. Vaccine-induced immunity is the only promising solution.
There is continued need for phase 2 & 3 vaccine trials to reach long-term, large-scale immunity of the entire European population. VACCELERATE will be the pan-European backbone accelerating phase 2 & 3 COVID-19 vaccine trials.
The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct.
VACCELERATE constitutes the rapid response single entry-point to stakeholders from public health authorities to vaccine developers, to address respective needs and kick-start specifically phase 2 & 3 vaccine trials.
VACCELERATE conducts capacity mapping of clinical trial and laboratory sites to identify suitable sites for individual phase 2 & 3 vaccine trials. Capacity building via training will increase quality in sites across Europe. Volunteer registries facilitate patient recruitment. Access to laboratory sites and a standardised set of assays essential for clinical phase 2 & 3 trials is provided.
A harmonised European approach to vaccine trials is enabled by aligning educational standards, coordination of laboratory support and providing standardised assays and trial protocols. Harmonised data collection, open data sharing and pooling of data for stronger analysis enables data standardisation.
VACCELERATE offers solutions for characteristic vaccine development issues during pandemics by closing gaps in public health knowledge and improving knowledge transfer.
VACCELERATE amalgamates the vast but scattered expertise across Europe into one network to deliver strategic scientific leadership and guidance on vaccine trials in Europe.
Beyond the COVID-19 pandemic, it will be an established pandemic preparedness network, ready to face emerging future pandemics, as well as a pivot in Europe?s capacity to develop vaccines.
All Grantees
Ecrin European Clinical Research Infrastructure Network; Medizinische Universitaet Wien; Region Hovedstaden; Folkehelseinstituttet; European University - Cyprus Ltd; Universita Degli Studi Di Verona; Fundacion Publica Galega de Investigacion Biomedica Inibic; Universiteit Antwerpen; University of Galway; Institut National de la Sante Et de la Recherche Medicale; Klinikum Der Universitaet Zu Koeln; University College Dublin, National University of Ireland, Dublin; Ministry of Health; Masarykova Univerzita; Instituto de Salud Carlos Iii; Faculty of Medicine, Universityersity of Belgrade; Universitaet Bern; Uniwersytet Medyczny W Bialymstoku; Servicio Madrileno de Salud; Orszagos Koranyi Pulmonologiai Intezet; Fundacion Para la Gestion de la Investigacion En Salud de Sevilla; Unidade Local de Saude de Santo Antonio Epe; Universitair Medisch Centrum Utrecht; Stichting European Clinical Research Alliance On Infectious Diseases; Viesoji Istaiga Vilniaus Universiteto Ligonine Santaros Klinikos; Karolinska Institutet; Kentro Klinikis Epidimiologias Kaiekvasis Nosimaton; European Vaccine Initiative E.V; Universite Paris Cite; Hacettepe Universitesi; Fundacion Para la Investigacion Biomedica Del Hospital Universiatrio la Paz; Region Stockholm; Biomedicinske Centrum Slovenskej Akademie Vied, Verejna Vyskumna Institucia; Universitetet I Bergen
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
